Trial · NCT00074711
Adding Phosphorus to Osteoporosis Drug Treatment
NCT00074711, Phase 2, Completed, Creighton University; results first posted 2016-07-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adding Phosphorus to Osteoporosis Drug Treatment. Trials, record NCT00074711. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00074711
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adding Phosphorus to Osteoporosis Drug Treatment
- NCT number
- NCT00074711
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 241 participants, actual
- Lead sponsor
- Creighton University
- Conditions
- Osteoporosis, Osteopenia
- Interventions
- Calcium carbonate, Calcium Phosphate
- First posted
- 2003-12-22
- Last updated
- 2016-07-06
- Results first posted
- 2016-07-06
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. | Measured at Baseline | Bone mineral density (BMD, measured by dual X-ray absorptiometry - DEXA) measured at several intervals during the study. BMD measured as grams per square centimeter (g/cm2). |
| Primary | Bone Mineral Density (BMD) Under Treatment With an Anabolic Agent (Teriparatide). | 12 months | The principle outcome measure was change in bone mineral density (BMD) under treatment with an anabolic agent (teriparatide). |
| Secondary | Change From Baseline in Serum Phosphorus, Serum Creatinine, Serum Calcium at 12 Months | Measured at baseline and 12 months | |
| Secondary | Change From Baseline in Urinary Calcium to Creatinine Ratio, Urinary Phosphorus to Creatinine Ratio at 12 Months | Measured at baseline and 12 months | |
| Secondary | Change From Baseline in Urinary N-telopeptide at 12 Months | Measured at baseline and 12 months | |
| Secondary | Change From Baseline in Urinary Hydroxyproline to Creatinine Ratio at 12 Months | Measured at baseline and 12 months |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. | Measured at Baseline | Postmenopausal women with spinal osteoporosis. | g/cm2 | MEAN |
| PRIMARY | Bone Mineral Density (BMD) Under Treatment With an Anabolic Agent (Teriparatide). | 12 months | Participants that completed study. | g/cm2 | MEAN |
| SECONDARY | Change From Baseline in Serum Phosphorus, Serum Creatinine, Serum Calcium at 12 Months | Measured at baseline and 12 months | mg/dl | MEAN | |
| SECONDARY | Change From Baseline in Urinary Calcium to Creatinine Ratio, Urinary Phosphorus to Creatinine Ratio at 12 Months | Measured at baseline and 12 months | g/g | MEAN | |
| SECONDARY | Change From Baseline in Urinary N-telopeptide at 12 Months | Measured at baseline and 12 months | nmol bce/mmol | MEAN | |
| SECONDARY | Change From Baseline in Urinary Hydroxyproline to Creatinine Ratio at 12 Months | Measured at baseline and 12 months | micromol/mmol | MEAN |
Source ClinicalTrials.gov
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. | Calcium Phosphate Treatment Group | Baseline (Hip) | 0.76 | Standard Deviation 0.11 | g/cm2 |
| Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. | Calcium Carbonate Treatment Group | Baseline (Hip) | 0.78 | Standard Deviation 0.10 | g/cm2 |
| Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. | Calcium Phosphate Treatment Group | Baseline (Spine) | 0.88 | Standard Deviation 0.12 | g/cm2 |
| Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. | Calcium Carbonate Treatment Group | Baseline (Spine) | 0.86 | Standard Deviation 0.12 | g/cm2 |
| Bone Mineral Density (BMD) Under Treatment With an Anabolic Agent (Teriparatide). | Calcium Phosphate Treatment Group | Hip Bone Mineral Density | 0.01680 | Standard Error 0.00227 | g/cm2 |
| Bone Mineral Density (BMD) Under Treatment With an Anabolic Agent (Teriparatide). | Calcium Carbonate Treatment Group | Hip Bone Mineral Density | 0.01450 | Standard Error 0.00203 | g/cm2 |
| Bone Mineral Density (BMD) Under Treatment With an Anabolic Agent (Teriparatide). | Calcium Phosphate Treatment Group | Spine Bone Mineral Density | 0.0609 | Standard Error 0.00356 | g/cm2 |
| Bone Mineral Density (BMD) Under Treatment With an Anabolic Agent (Teriparatide). | Calcium Carbonate Treatment Group | Spine Bone Mineral Density | 0.0607 | Standard Error 0.00336 | g/cm2 |
| Change From Baseline in Serum Phosphorus, Serum Creatinine, Serum Calcium at 12 Months | Calcium Phosphate Treatment Group | S Phos | 0.139 | Standard Error 0.045 | mg/dl |
| Change From Baseline in Serum Phosphorus, Serum Creatinine, Serum Calcium at 12 Months | Calcium Carbonate Treatment Group | S Phos | 0.245 | Standard Error 0.042 | mg/dl |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Calcium Phosphate Treatment Group | 120 | |
| Overall Study | STARTED | Calcium Carbonate Treatment Group | 121 | |
| Overall Study | COMPLETED | Calcium Phosphate Treatment Group | 105 | |
| Overall Study | COMPLETED | Calcium Carbonate Treatment Group | 106 | |
| Overall Study | NOT COMPLETED | Calcium Phosphate Treatment Group | 15 | |
| Overall Study | NOT COMPLETED | Calcium Carbonate Treatment Group | 15 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Death | Cardiac disorders | Calcium Phosphate Treatment Group | 1 | 105 | 1 |
| serious | Death | Cardiac disorders | Calcium Carbonate Treatment Group | 0 | 106 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Calcium Phosphate Treatment Group | ||
| Total, all-cause mortality | Calcium Carbonate Treatment Group | ||
| Total, other adverse events | Calcium Phosphate Treatment Group | 0 | 105 |
| Total, other adverse events | Calcium Carbonate Treatment Group | 0 | 106 |
| Total, serious adverse events | Calcium Phosphate Treatment Group | 1 | 105 |
| Total, serious adverse events | Calcium Carbonate Treatment Group | 0 | 106 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AR048846 | Bone-Sparing by Ca Salts With & Without Extra Phosphorus | HEANEY, ROBERT P | CREIGHTON UNIVERSITY | NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES | 2003 to 2008 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Calcium Phosphate Treatment Group vs Calcium Carbonate Treatment Group: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00074711
GET https://conductscience.org/api/trials/v1/NCT00074711/results?page=2